<DOC>
	<DOCNO>NCT03068065</DOCNO>
	<brief_summary>This 24-week single-center , open-label , parallel control group compare gliclazide , liraglutide , metformin effect diabetes nonalcoholic fatty liver disease .</brief_summary>
	<brief_title>Antidiabetic Effects Intrahepatic Fat</brief_title>
	<detailed_description>Following enrollment , eligible participant randomize ( 1:1:1 ) use computer-generated random number metformin ( Glucophage , Bristol-Myers Squibb ) , liraglutide ( Victoza , Novo Nordisk ) , gliclazide ( Diamicron , Servier ) group . All patient inform proper diet exercise . For metformin group ( n = 31 ) , dosage 250 mg thrice day first week , 500 mg thrice day second week , 1000 mg twice day third week conclusion study . For gliclazide group ( n = 31 ) , initial dosage 30 mg breakfast , gradually titrate maximum 120 mg/day achieve fast capillary plasma glucose &lt; 7.0 mmol/L . For liraglutide group ( n = 31 ) , dosage 0.6 mg/day first week , 1.2 mg/day second week , 1.8 mg/day third week conclusion study.At end study , data collect analyzed .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>1 . Age : 1870 year ; 2 . Type 2 diabetes mellitus ; 3 . Not use antidiabetic drug within 3 month ; 4 . HbA1c ( 710 % ) ; 5 . Presence fatty liver disease ( hepatic fat content ≥ 20 % quantitative ultrasonography ) ; 6 . Female subjects：postmenopausal woman , take contraceptive measure three month test screen persist throughout experimental period ; 7 . Body mass index ( BMI ) 2035kg/m2 , stable Weight 3 month ( less 10 % volatility ) ; 8. patient sign informed consent . 1 . Used antidiabetic drug possible hepatic steatosis associate drug within past three month ; 2 . Suffering pancreatitis pancreatic disease similar history ; 3 . GLP1 analogs sulfonylurea allergy history ; 4 . Liver dysfunction ( aspartate aminotransferase ≥ 2.5 time normalupper limit ) ; 5 . Moderate severe renal insufficiency ( eGFR &lt; 60ml/min/1.73m2 , calculate accord MDRD ) ; 6 . Female subject drink &gt; 14 unit / week ; male subject drink &gt; 21 units/week ; 7 . A history metabolic autoimmune liver diseases viral hepatitis disease ; 8 . A history medullary thyroid carcinoma , multiple endocrine neoplasia 2 family history ; 9 . Congestive heart failure ( NYHA grade Ⅲ Ⅳ grade ) ; 10 . Severe gastrointestinal disease ; 11 . Other serious concomitant disease ; 12 . Pregnant planning pregnancy ; 13 . The researcher believe subject proliferative retinopathy macular degeneration need urgentl treatment ; 14 . Subjects use unknown ingredient non herbal medicine preparation local medicine , researcher believe test dose traditional Chinese medicine adjust disabled .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Liraglutide</keyword>
	<keyword>Metformin</keyword>
	<keyword>Gliclazide</keyword>
</DOC>